Up­dat­ed: US sees spike in Paxlovid us­age as Mer­ck­'s mol­nupi­ravir and As­traZeneca's Evusheld are slow­er off the shelf

New da­ta from HHS show that more than 162,000 cours­es of Pfiz­er’s Covid-19 an­tivi­ral Paxlovid were ad­min­is­tered across the US over the past week, con­tin­u­ing a streak of in­creased us­age of the pill, and sig­nal­ing not on­ly ris­ing case num­bers but more aware­ness of how to ac­cess it.

In com­par­i­son to this week, about 670,000 cours­es of the Pfiz­er pill have been ad­min­is­tered across the first five months since Paxlovid has been on the US mar­ket, av­er­ag­ing about 33,000 cours­es ad­min­is­tered per week in that time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER